' /> ' /> ' />
A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Intensive Course Bookmark and Share

Intensive Course in Cancer Risk Assessment Overview

 
 
To help address the growing demand for clinicians with interdisciplinary knowledge and skills in the practice of genetic cancer risk assessment (GCRA), the multifaceted Intensive Course in Cancer Risk Assessment and its Clinical Cancer Genetics Community of Practice (CCGCoP) leverage the expertise of the academic health center through Web-based tools to deliver accessible, evidence-based cancer genetics and genomics training, professional development, and practice-centered support at the point of care. The mission of the Intensive Course and CCGCoP is to increase the number of clinicians who are able to translate rapid advances in genetics and genomics into cancer risk assessment, management, and prevention practice. Realizing the promise of personalized medicine by promoting best practices in the delivery of GCRA services across the U.S. and internationally is the ultimate goal of the Clinical Cancer Genetics Community of Practice.
 
 
Objectives
 
At the conclusion of the course the participants should be able to:
  • Integrate cancer genetics and oncology knowledge into clinical practice
  • Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process
  • Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions
  • Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration
  • Discuss clinical research methodologies in cancer genetics epidemiology and cancer prevention trials for high-risk cohorts
  • Recognize the roles and practical issues related to Human Subjects Protections, Informed Consent, Institutional Review Board and HIPAA in clinical research
  • Provide resources and information on current hereditary cancer registries, cancer epidemiology and cancer prevention studies to patients and professional colleagues
  • Use research training and support to participate in collaborative research activities
  • Realize greater professional self-efficacy related to cancer risk counseling and research participation skills
  • Incorporate web-based resources into ongoing practice-based education, professional development and research network support
 
 
Reaching Clinicians Around the Globe
 
City of Hope's Intensive Course in Cancer Risk Assessment has trained health care professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay. Participation of the Intensive Course alumni in the ongoing practice-centered professional development activities hosted by City of Hope has evolved into a dynamic international Clinical Cancer Genetics Community of Practice.
 
 
 
 
 
 
 
 
 
 

Accreditation

CME Credits
Accreditation Statement: Accreditation in process

Credit Designation: City of Hope designates this educational activity for a maximum of (TBD) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The following may apply CME Category 1 credit for license renewal:

Registered Nurses: Nurses may report up to (TBD) credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.

Physician’s Assistants: The National Commission on Certification of Physician Assistants states that AMA accredited Category 1 courses are acceptable for CME requirements for recertification.

Genetic Counselor CEUs: The American Board of Genetic Counseling (ABGC) accepts CEUs approved by the National Society for Genetic Counselors (NSGC) for purposes of recertification. This event has been submitted to NSGC for approval of Category 1 CEUs and is approved for (TBD) CEUs and (TBD) Contact Hours.

Disclosure
The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
 
No partial credit will be given. Participants should claim only those hours of credit that they actually spent at the educational activity.
 

Intensive Course Application Requirement

Application Deadline
 
Enrollment for the 2016 course began on May 22, 2015 and closed on August 1, 2015.
 
Requirements
Please read all terms stated below before submitting application.

To receive full course credit, and certificate of course completion, course participants will be required to:
 
  • Participate in all distance and on-campus course related activities.
  • Complete all distance learning lecture modules delivered via Website and USB drive (flashdrive) interface by given deadlines.
  • Complete all pre- and post-course surveys, knowledge questionnaires, evaluations, and assignments as directed.
  • Agree to complete prescribed post-course professional development activities as outlined in the course syllabus. Some activities are required to be completed at 6-months post training and some must be completed by 1-year post training.
 
Selection Criteria
Preferred candidates are oncology or genetics-trained physicians, advanced practice nurses and genetic counselors currently providing or planning to initiate community-based clinical cancer genetics services.
 
 
How to Apply
 
Complete the Intensive Course Application and submit the following required documents:
 
  • Completed application form
  • Letter from your institution indicating that protected time will be provided for course participation, and statement that you will have institutional support to provide cancer risk assessment upon return to your community (if applicable).
  • Current curriculum vitae (CV)
  • Mini-biography
  • Current headshot
 
Please NOTE: Applications will not be accepted without the items listed above.
 
Submit all of the above via regular mail, email or fax to:
 
Gloria Nuñez, Conference Coordinator
City of Hope
Division of Clinical Cancer Genetics, Mod 173
1500 East Duarte Road
Duarte, CA 91010-3000

Fax:
626-930-5495

Email:
cgep@coh.org (note subject as "Intensive Course")
 
Acceptance
Applicants will be notified of acceptance by September 30, 2015, via e-mail. The non-refundable course fee (TBD) will be due on or before October 30, 2015.
 

Faculty

Course Co-directors
Jeffrey Weitzel, M.D.
Chief, Division of Clinical Cancer Genetics

Kathleen R. Blazer, Ed.D., M.S., L.C.G.C.
Clinical Assistant Professor, Division of Clinical Cancer Genetics

City of Hope Faculty
Danielle Castillo, BS
Research Associate II
 
Josef Herzog, BS
Staff Scientist
 
Bita Nehoray, MS, LCGC
Cancer Risk Counselor
 
Lacolle Robinson, BA, CCRP
Pedigree Project Specialist
 
Christina Rybak, MS, LCGC
Cancer Risk Counselor
 
Sharon Sand, BA, CCRP
Clinical Research Associate II
 
Ilana Solomon, ScM, MA, CGC
Cancer Risk Counselor
 
Mariana Niell-Swiller, MS, LCGC
Assistant Director, CSPPN
Cancer Risk Counselor
 
Thomas Slavin, MD, FACMG, DABMD
Clinical Assistant Professor
 
Lucille Leong, MD
Associate Director, Clinical Affairs
Medical Oncology & Therapeutics Research
 
Robert Morgan, Jr., MD, FACP
Section Head, Neuro-Oncology
Medical Oncology & Therapeutics Research
 
Sharon Wilczynski, MD, PhD
Director, Cytology
Department of Anatomic Pathology

Guest Faculty
Patricia Ashton-Prolla, MD
Clinical Geneticist and Professor
Federal University of Rio Grande do Sul, Brazil
 
Randall Burt, MD
University of Utah: Emeritus Professor of Medicine
Huntsman Cancer Institute (HCI): Emeritus Director of Prevention and Outreach
 
Fergus Couch, PhD
Professor
Mayo Clinic
Rochester, MN
 
Julie Culver, MS, LCGC
Genetic Counselor
USC Norris Comprehensive Cancer Center
Los Angeles, CA
 
Kevin A. Davies, PhD
Editor-in-Chief
Bio-IT World
Needham MA
 
Charis Eng, MD, PhD, FACP
Sondra J and Stephen R Hardis Chair of Cancer Genomic Medicine;
Chair, Genomic Medicine Institute; Director, Center for Personalized Genetic Healthcare
Cleveland Clinic, Cleveland, OH
 
Carol Fabian, MD
Director
Breast Cancer Prevention & Survivorship Centers
University of Kansas Hospital and Medical Pavilion
 
Judy Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Dana Farber Cancer Institute
Boston, MA
 
Heather Hampel, MS, CGC
Associate Director, Division of Human Genetics
The Ohio State University Comprehensive Cancer Center
 
Karen Hurley, PhD
Adjunct Assistant Faculty
Memorial Sloan Kettering Cancer Center
New York, NY
 
Sonia Kupfer, MD
Assistant Professor of Medicine
Section of Gastroenterology
University of Chicago Medical Center
 
Lucy R.  Langer, MD
Medical Oncologist, Co-Medical Director
Genetic Risk Evaluation & Testing Program
US Oncology
Portland, OR

Katrina Lowstuter, MS, CGC
Genetic Counselor
USC Norris Comprehensive Cancer Center
 
Patrick Lynch, MD
Professor, Department of Gastroenterology, Hepatology, & Nutrition
U.T. M.D. Anderson Cancer Center
Houston, TX
 
Lindsay Middelton, RN, GC
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD
 
Therese Mulvey, MD
Physician-in-Chief, Medical Oncologist
Southcoast Center for Cancer Care
Fairhaven, MA
 
Rebecca Nagy, MS, CGC
Assistant Professor
Clinical Division of Human Genetics
The Ohio State University
 
Kenneth Offit, MD
Service Chief
Memorial Sloan Kettering Cancer Center
New York, NY
 
Colin Pritchard, MD, PhD
Assistant Professor, Laboratory Medicine
Associate Director, Clinical Molecular
University of Washington
 
Charité Ricker, MS, CGC
Genetic Counselor
Clinical Instructor of Medicine
Cancer Genetics Program
LAC+USC Medical Center
Los Angeles, CA
 
Mark Robson, MD
Clinical Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
Juan-Sebastian Saldivar, MD, FACMG
Vice President, Clinical Services and Medical Affairs
Sequenom CMM, Center for Molecular Medicine
San Diego, CA
 
April Sorrell, MD
Cancer Genetics Specialist
Children’s Hospital of San Antonio/
Baylor College of Medicine Pediatric Hematology/Oncology
San Antonio, TX
 
Louise Strong, MD
Sue and Radcliffe Killam Chair
Professor of Cancer Genetics
Department of Genetics
U.T. MD Anderson Cancer Center
Houston, Texas
 
Janet Williams, MS, LCGC
Director, Research Genetic Counselors
Genomic Medicine Institute
Geisinger Health System
Danville, Pa 17822
 
Marc Williams, MD, FAAP, FACMG
Director, Genomic Medicine Institute
Geisinger Health System
Danville, PA


City of Hope Planning Committee
  • Kathleen R. Blazer, EdD, MS, LCGC, Course Co-Director; Associate Director, CGEP
  • Bita Nehoray, MS, LCGC, Cancer Risk Counselor
  • Mariana Niell-Swiller, MS, LCGC, Assistant Director, CSPPN; Cancer Risk Counselor
  • Gloria Nuñez, MPH, BA,  Administrative Program Coordinator
  • Lacolle Robinson, BA, CCRP, Pedigree Project Specialist
  • Christina Rybak, MS, LCGC, Cancer Risk Counselor
  • Sharon Sand, CCRP, Clinical Research Associate III
  • Thomas Slavin, Jr., MD, FACMG, Clinical Assistant Professor
  • Ilana Solomon, ScM, MA, LCGC, Cancer Risk Counselor
  • Lily VanTongeren, BA, Clinical Research and Education Assistant
  • Jeffrey N. Weitzel, MD, Course Co-Director; Chief
 

Intensive Course Alumni

City of Hope's Intensive Course in Cancer Risk Assessment has trained health professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay.
 
 
 
 
 
 

Intensive Course Description

 
 
 
The Intensive Course and Clinical Cancer Genetics Community of Practice embody the tenets of practice-centered situated learning theory. Distance delivery of a modular curriculum responds to the practical time constraints of working clinicians and allows for flexible, self-directed study (e.g., oncologists can opt out of basic oncology content and focus more study time on genetics content, etc.). Concurrent participation in Working Group Clinical Cancer Genetics Web conferences reinforces didactic learning and Genetic Cancer Risk Assessment (GCRA) skills development. Participants have the option of participating in one of two training tracks to customize training to meet their learning needs.
 
 
Click the individual track link below for more information, including fees, and to download the track Calendar for 2016 Winter (calendar in progress).
 
 
Both tracks include distance didactic learning with corresponding Web conference reviews, and case-based training with Working Group Web conferences. Only Track 1 Full Spectrum Multi-modal Training includes four days of face-to-face program development workshops.
 
Upon completion of training, all participants receive support to apply new learning to practice through 12 months of self-directed engagement and activities as members of the Clinical Cancer Genetics Community of Practice.
 
 
 
 
 

Intensive Course Track 1: Full Spectrum Multi-modal Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 6, 2015, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 13, 2015 through February 19, 2016
 
Phase 2:

Four days of face-to-face Cancer Genetics Workshops on-campus at City of Hope in Duarte, CA.
 
Dates:  February 23 - 26, 2016
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before October 1, 2015)

MDs:  $2,000
RNs/GCs/Fellows/Pa-Cs:  $1,600
Industry:  $3,000
(Fees do not including travel or hotel)
 
 
IC 2016W Curriculum Overview - New 2016 Curriculum coming soon
 
 
 

Intensive Course Track 2--Full Spectrum Distance-only Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 6, 2015, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 13, 2015 through February 19, 2016
 
Phase 2: (no on-campus workshops)
 

Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before October 1, 2015)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 
IC 2016W Curriculum Overview - New 2016 Curriculum coming soon

 
 

Clinical Cancer Genetics Community of Practice

City of Hope Clinical Cancer Genetics Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.
 
Working Group
 
Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team.
 
TICGR Topics in Cancer Genetics Research
 
Topics in Clinical Cancer Genetics (TICGR) is a weekly one-hour CME-accredited web-conference seminar series focused on timely issues in clinical cancer genetics, cancer epidemiology and cancer genetics research, alternating between didactic lectures, case-based literature reviews and basic research journal club.
 

A Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning.
 
Knowledge Center
 
Knowledge Center Information coming soon
 

A large research group of over 40 collaborating sites in the 40 collaborating sites in the United States, Mexico, and South America. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 

Intensive Course

Intensive Course in Cancer Risk Assessment Overview

 
 
To help address the growing demand for clinicians with interdisciplinary knowledge and skills in the practice of genetic cancer risk assessment (GCRA), the multifaceted Intensive Course in Cancer Risk Assessment and its Clinical Cancer Genetics Community of Practice (CCGCoP) leverage the expertise of the academic health center through Web-based tools to deliver accessible, evidence-based cancer genetics and genomics training, professional development, and practice-centered support at the point of care. The mission of the Intensive Course and CCGCoP is to increase the number of clinicians who are able to translate rapid advances in genetics and genomics into cancer risk assessment, management, and prevention practice. Realizing the promise of personalized medicine by promoting best practices in the delivery of GCRA services across the U.S. and internationally is the ultimate goal of the Clinical Cancer Genetics Community of Practice.
 
 
Objectives
 
At the conclusion of the course the participants should be able to:
  • Integrate cancer genetics and oncology knowledge into clinical practice
  • Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process
  • Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions
  • Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration
  • Discuss clinical research methodologies in cancer genetics epidemiology and cancer prevention trials for high-risk cohorts
  • Recognize the roles and practical issues related to Human Subjects Protections, Informed Consent, Institutional Review Board and HIPAA in clinical research
  • Provide resources and information on current hereditary cancer registries, cancer epidemiology and cancer prevention studies to patients and professional colleagues
  • Use research training and support to participate in collaborative research activities
  • Realize greater professional self-efficacy related to cancer risk counseling and research participation skills
  • Incorporate web-based resources into ongoing practice-based education, professional development and research network support
 
 
Reaching Clinicians Around the Globe
 
City of Hope's Intensive Course in Cancer Risk Assessment has trained health care professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay. Participation of the Intensive Course alumni in the ongoing practice-centered professional development activities hosted by City of Hope has evolved into a dynamic international Clinical Cancer Genetics Community of Practice.
 
 
 
 
 
 
 
 
 
 

Accreditation

Accreditation

CME Credits
Accreditation Statement: Accreditation in process

Credit Designation: City of Hope designates this educational activity for a maximum of (TBD) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The following may apply CME Category 1 credit for license renewal:

Registered Nurses: Nurses may report up to (TBD) credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.

Physician’s Assistants: The National Commission on Certification of Physician Assistants states that AMA accredited Category 1 courses are acceptable for CME requirements for recertification.

Genetic Counselor CEUs: The American Board of Genetic Counseling (ABGC) accepts CEUs approved by the National Society for Genetic Counselors (NSGC) for purposes of recertification. This event has been submitted to NSGC for approval of Category 1 CEUs and is approved for (TBD) CEUs and (TBD) Contact Hours.

Disclosure
The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
 
No partial credit will be given. Participants should claim only those hours of credit that they actually spent at the educational activity.
 

Application Requirement

Intensive Course Application Requirement

Application Deadline
 
Enrollment for the 2016 course began on May 22, 2015 and closed on August 1, 2015.
 
Requirements
Please read all terms stated below before submitting application.

To receive full course credit, and certificate of course completion, course participants will be required to:
 
  • Participate in all distance and on-campus course related activities.
  • Complete all distance learning lecture modules delivered via Website and USB drive (flashdrive) interface by given deadlines.
  • Complete all pre- and post-course surveys, knowledge questionnaires, evaluations, and assignments as directed.
  • Agree to complete prescribed post-course professional development activities as outlined in the course syllabus. Some activities are required to be completed at 6-months post training and some must be completed by 1-year post training.
 
Selection Criteria
Preferred candidates are oncology or genetics-trained physicians, advanced practice nurses and genetic counselors currently providing or planning to initiate community-based clinical cancer genetics services.
 
 
How to Apply
 
Complete the Intensive Course Application and submit the following required documents:
 
  • Completed application form
  • Letter from your institution indicating that protected time will be provided for course participation, and statement that you will have institutional support to provide cancer risk assessment upon return to your community (if applicable).
  • Current curriculum vitae (CV)
  • Mini-biography
  • Current headshot
 
Please NOTE: Applications will not be accepted without the items listed above.
 
Submit all of the above via regular mail, email or fax to:
 
Gloria Nuñez, Conference Coordinator
City of Hope
Division of Clinical Cancer Genetics, Mod 173
1500 East Duarte Road
Duarte, CA 91010-3000

Fax:
626-930-5495

Email:
cgep@coh.org (note subject as "Intensive Course")
 
Acceptance
Applicants will be notified of acceptance by September 30, 2015, via e-mail. The non-refundable course fee (TBD) will be due on or before October 30, 2015.
 

Faculty

Faculty

Course Co-directors
Jeffrey Weitzel, M.D.
Chief, Division of Clinical Cancer Genetics

Kathleen R. Blazer, Ed.D., M.S., L.C.G.C.
Clinical Assistant Professor, Division of Clinical Cancer Genetics

City of Hope Faculty
Danielle Castillo, BS
Research Associate II
 
Josef Herzog, BS
Staff Scientist
 
Bita Nehoray, MS, LCGC
Cancer Risk Counselor
 
Lacolle Robinson, BA, CCRP
Pedigree Project Specialist
 
Christina Rybak, MS, LCGC
Cancer Risk Counselor
 
Sharon Sand, BA, CCRP
Clinical Research Associate II
 
Ilana Solomon, ScM, MA, CGC
Cancer Risk Counselor
 
Mariana Niell-Swiller, MS, LCGC
Assistant Director, CSPPN
Cancer Risk Counselor
 
Thomas Slavin, MD, FACMG, DABMD
Clinical Assistant Professor
 
Lucille Leong, MD
Associate Director, Clinical Affairs
Medical Oncology & Therapeutics Research
 
Robert Morgan, Jr., MD, FACP
Section Head, Neuro-Oncology
Medical Oncology & Therapeutics Research
 
Sharon Wilczynski, MD, PhD
Director, Cytology
Department of Anatomic Pathology

Guest Faculty
Patricia Ashton-Prolla, MD
Clinical Geneticist and Professor
Federal University of Rio Grande do Sul, Brazil
 
Randall Burt, MD
University of Utah: Emeritus Professor of Medicine
Huntsman Cancer Institute (HCI): Emeritus Director of Prevention and Outreach
 
Fergus Couch, PhD
Professor
Mayo Clinic
Rochester, MN
 
Julie Culver, MS, LCGC
Genetic Counselor
USC Norris Comprehensive Cancer Center
Los Angeles, CA
 
Kevin A. Davies, PhD
Editor-in-Chief
Bio-IT World
Needham MA
 
Charis Eng, MD, PhD, FACP
Sondra J and Stephen R Hardis Chair of Cancer Genomic Medicine;
Chair, Genomic Medicine Institute; Director, Center for Personalized Genetic Healthcare
Cleveland Clinic, Cleveland, OH
 
Carol Fabian, MD
Director
Breast Cancer Prevention & Survivorship Centers
University of Kansas Hospital and Medical Pavilion
 
Judy Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Dana Farber Cancer Institute
Boston, MA
 
Heather Hampel, MS, CGC
Associate Director, Division of Human Genetics
The Ohio State University Comprehensive Cancer Center
 
Karen Hurley, PhD
Adjunct Assistant Faculty
Memorial Sloan Kettering Cancer Center
New York, NY
 
Sonia Kupfer, MD
Assistant Professor of Medicine
Section of Gastroenterology
University of Chicago Medical Center
 
Lucy R.  Langer, MD
Medical Oncologist, Co-Medical Director
Genetic Risk Evaluation & Testing Program
US Oncology
Portland, OR

Katrina Lowstuter, MS, CGC
Genetic Counselor
USC Norris Comprehensive Cancer Center
 
Patrick Lynch, MD
Professor, Department of Gastroenterology, Hepatology, & Nutrition
U.T. M.D. Anderson Cancer Center
Houston, TX
 
Lindsay Middelton, RN, GC
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD
 
Therese Mulvey, MD
Physician-in-Chief, Medical Oncologist
Southcoast Center for Cancer Care
Fairhaven, MA
 
Rebecca Nagy, MS, CGC
Assistant Professor
Clinical Division of Human Genetics
The Ohio State University
 
Kenneth Offit, MD
Service Chief
Memorial Sloan Kettering Cancer Center
New York, NY
 
Colin Pritchard, MD, PhD
Assistant Professor, Laboratory Medicine
Associate Director, Clinical Molecular
University of Washington
 
Charité Ricker, MS, CGC
Genetic Counselor
Clinical Instructor of Medicine
Cancer Genetics Program
LAC+USC Medical Center
Los Angeles, CA
 
Mark Robson, MD
Clinical Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
Juan-Sebastian Saldivar, MD, FACMG
Vice President, Clinical Services and Medical Affairs
Sequenom CMM, Center for Molecular Medicine
San Diego, CA
 
April Sorrell, MD
Cancer Genetics Specialist
Children’s Hospital of San Antonio/
Baylor College of Medicine Pediatric Hematology/Oncology
San Antonio, TX
 
Louise Strong, MD
Sue and Radcliffe Killam Chair
Professor of Cancer Genetics
Department of Genetics
U.T. MD Anderson Cancer Center
Houston, Texas
 
Janet Williams, MS, LCGC
Director, Research Genetic Counselors
Genomic Medicine Institute
Geisinger Health System
Danville, Pa 17822
 
Marc Williams, MD, FAAP, FACMG
Director, Genomic Medicine Institute
Geisinger Health System
Danville, PA


City of Hope Planning Committee
  • Kathleen R. Blazer, EdD, MS, LCGC, Course Co-Director; Associate Director, CGEP
  • Bita Nehoray, MS, LCGC, Cancer Risk Counselor
  • Mariana Niell-Swiller, MS, LCGC, Assistant Director, CSPPN; Cancer Risk Counselor
  • Gloria Nuñez, MPH, BA,  Administrative Program Coordinator
  • Lacolle Robinson, BA, CCRP, Pedigree Project Specialist
  • Christina Rybak, MS, LCGC, Cancer Risk Counselor
  • Sharon Sand, CCRP, Clinical Research Associate III
  • Thomas Slavin, Jr., MD, FACMG, Clinical Assistant Professor
  • Ilana Solomon, ScM, MA, LCGC, Cancer Risk Counselor
  • Lily VanTongeren, BA, Clinical Research and Education Assistant
  • Jeffrey N. Weitzel, MD, Course Co-Director; Chief
 

Intensive Course Alumni

Intensive Course Alumni

City of Hope's Intensive Course in Cancer Risk Assessment has trained health professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay.
 
 
 
 
 
 

Intensive Course Description

Intensive Course Description

 
 
 
The Intensive Course and Clinical Cancer Genetics Community of Practice embody the tenets of practice-centered situated learning theory. Distance delivery of a modular curriculum responds to the practical time constraints of working clinicians and allows for flexible, self-directed study (e.g., oncologists can opt out of basic oncology content and focus more study time on genetics content, etc.). Concurrent participation in Working Group Clinical Cancer Genetics Web conferences reinforces didactic learning and Genetic Cancer Risk Assessment (GCRA) skills development. Participants have the option of participating in one of two training tracks to customize training to meet their learning needs.
 
 
Click the individual track link below for more information, including fees, and to download the track Calendar for 2016 Winter (calendar in progress).
 
 
Both tracks include distance didactic learning with corresponding Web conference reviews, and case-based training with Working Group Web conferences. Only Track 1 Full Spectrum Multi-modal Training includes four days of face-to-face program development workshops.
 
Upon completion of training, all participants receive support to apply new learning to practice through 12 months of self-directed engagement and activities as members of the Clinical Cancer Genetics Community of Practice.
 
 
 
 
 

Track 1: Full Spectrum Multi-modal Training

Intensive Course Track 1: Full Spectrum Multi-modal Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 6, 2015, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 13, 2015 through February 19, 2016
 
Phase 2:

Four days of face-to-face Cancer Genetics Workshops on-campus at City of Hope in Duarte, CA.
 
Dates:  February 23 - 26, 2016
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before October 1, 2015)

MDs:  $2,000
RNs/GCs/Fellows/Pa-Cs:  $1,600
Industry:  $3,000
(Fees do not including travel or hotel)
 
 
IC 2016W Curriculum Overview - New 2016 Curriculum coming soon
 
 
 

Track 2: Full Spectrum Distance-only Training

Intensive Course Track 2--Full Spectrum Distance-only Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 6, 2015, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 13, 2015 through February 19, 2016
 
Phase 2: (no on-campus workshops)
 

Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before October 1, 2015)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
 
IC 2016W Curriculum Overview - New 2016 Curriculum coming soon

 
 

CCG Community of Practice

Clinical Cancer Genetics Community of Practice

City of Hope Clinical Cancer Genetics Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.
 
Working Group
 
Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team.
 
TICGR Topics in Cancer Genetics Research
 
Topics in Clinical Cancer Genetics (TICGR) is a weekly one-hour CME-accredited web-conference seminar series focused on timely issues in clinical cancer genetics, cancer epidemiology and cancer genetics research, alternating between didactic lectures, case-based literature reviews and basic research journal club.
 

A Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning.
 
Knowledge Center
 
Knowledge Center Information coming soon
 

A large research group of over 40 collaborating sites in the 40 collaborating sites in the United States, Mexico, and South America. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...